Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions

Abstract Introduction Although real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5 days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small fraction of patients with COVID-19 who are eligibl...

Descripció completa

Dades bibliogràfiques

Autors principals:	Abby E. Rudolph, Farid L. Khan, Tanya G. Singh, Srinivas Rao Valluri, Laura A. Puzniak, John M. McLaughlin
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2024-08-01
Col·lecció:	Infectious Diseases and Therapy
Matèries:	Disparities Nirmatrelvir/ritonavir Paxlovid Prescriptions filled Symptom onset date
Accés en línia:	https://doi.org/10.1007/s40121-024-01023-z
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!